Scholar Rock Holding (SRRK) Depreciation & Amortization (IS) (2024 - 2026)
Scholar Rock Holding's quarterly Depreciation & Amortization (IS) came in at $335000.0 in Q1 2026, down 14.76% year-on-year from $393000.0 in Q1 2025, and down 21.18% quarter-over-quarter from $425000.0 in Q4 2025.
Scholar Rock Holding has reported Depreciation & Amortization (IS) for 3 years, with the latest figure at $335000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (IS) fell 14.76% year-over-year to $335000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 5.72% YoY), and the FY2025 full-year result was $1.7 million, down 12.74% from the prior year.
- Depreciation & Amortization (IS) for Q1 2026 stood at $335000.0, down from $425000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (IS) was $598000.0 in Q1 2024, with the low at $335000.0 in Q1 2026.
- Average Depreciation & Amortization (IS) over 3 years is $432777.8, with a median of $423000.0 recorded in 2025.
- Peak annual rise in Depreciation & Amortization (IS) reached 18.72% in 2025, while the deepest fall reached 34.28% in 2025.
- Tracing SRRK's Depreciation & Amortization (IS) over 3 years: stood at $358000.0 in 2024, then grew by 18.72% to $425000.0 in 2025, then slipped by 21.18% to $335000.0 in 2026.
- The last three Depreciation & Amortization (IS) figures came in at $335000.0 (Q1 2026), $425000.0 (Q4 2025), and $423000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 127,436.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 335,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,000.00 |
| Dec 31, 2025 | 425,000.00 |
| Sep 30, 2025 | 423,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 598,000.00 |